JC2-11

Research use only, not for human use.

JC2-11 is an inhibitory compound for inflammation.JC2-11 inhibits the recruitment domain-containing proteins NLRC 4, atypical in melanoma 2 (AIM 2) and atypical (NC) inflammatory vesicles by disrupting reactive oxygen species (ROS) production and caspase-1 activity.

JC2-11 is an inhibitor ofinflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1.

——

Animal Model:C57BL/6 mice (8 weeks, female).Dosage:250 μg/mouse.Administration:Intraperitoneal injection; single dose.Result:Exhibited inhibitory effect on NC inflammatory body.

——

Metabolic Enzyme/Protease

Dehydrogenase

Dehydrogenase | IL Receptor | AIM2 | ROS | NOD-like Receptor (NLR) | Caspase

——

——

937820-89-8

302.3

C17H15FO4

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (330.80 mM)

C(/C=C/C1=CC(OC)=C(O)C=C1)(=O)C2=CC(F)=C(OC)C=C2

——

(-20℃)

With Ice Pack

≥ 2 years